Blockade of Tumor-Expressed PD-1 promotes lung cancer growth

Blockade of Tumor-Expressed PD-1 promotes lung cancer growth

Anti-PD-1 immunotherapy is the standard of care for treating many patients with non-small cell lung cancer (NSCLC), yet mechanisms of treatment failure are emerging. We present a case of NSCLC, who rapidly progressed during a trial (NCT02318771) combining palliative radiotherapy and pembrolizumab. P...

Full description

Bibliographic Details
Main Authors: Shisuo Du, Neal McCall, Kyewon Park, Qing Guan, Paolo Fontina, Adam Ertel, Tingting Zhan, Adam P. Dicker, Bo Lu
Format: Article
Language:English
Published: Taylor & Francis Group 2018-04-01
Series:OncoImmunology
Subjects:
pd-1
therapeutic resistance
immunotherapy
lung cancer
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1408747

Internet

http://dx.doi.org/10.1080/2162402X.2017.1408747

Similar Items